Absolute Contraindications Active malignancy Pregnancy and lactation Severe hypoglycemia disorders Known hypersensitivity to IGF-1 Active proliferative retinopathy Relative Contraindications Diabetes mellitus Renal impairment Cardiac impairment History of hyperplasia Family history of certain cancers Severe hepatic impairment Dosing & Administration Starting Dose 2050 mcg/day subcutaneously Begin at the lower end for sensitive patients Assess tolerance for 12 weeks before titration Therapeutic Range 50120 mcg/day for most indications Maximum dose: 200 mcg/day Individualize dosing based on response and tolerance Cycling Protocol 46 weeks on therapy 4 weeks off therapy Helps prevent receptor desensitization Supports long-term efficacy Administration Guidelines Hypoglycemia Prevention: Always administer IGF-1 LR3 with or shortly after carbohydrate-containing meals
Nonsteroidal antagonists of the mineralocorticoid receptor
FATIGUE REDUCTION AND EXERCISE CAPACITY IMPROVEMENTS By enhancing mitochondrial capacity and metabolic efficiency, 5-Amino-1MQ may reduce fatigue and improve exercise capacity
doi: 10.1210/jc.2008-0115 162 ChuffaLGLupi JniorLAda Maia LimaAF
The injection mechanism is triggered by a navy blue button on the end of the pen
Together, they can become part of a broader wellness strategy that includes coaching, nutrition, movement, sleep, hydration, and accountability